Ecog-acrin Cancer Research Group

This study tests whether giving precise, high-dose radiation (SAbR) to tumors before standard treatment (immunotherapy or pills) helps people with kidney cancer that has spread to 2-5 places in the body live longer. About 472 adults with this type of advanced kidney cancer will t…

This study tests whether adding the immunotherapy drug pembrolizumab to standard targeted therapy (TKIs) can eliminate leftover leukemia cells in people with chronic myeloid leukemia (CML). About 40 adults with stable disease but persistent low-level cancer markers will receive t…

This study looks at whether giving chemotherapy both before and after surgery helps people with stage II-III gallbladder cancer live longer than the usual approach of surgery followed by chemo. About 186 participants will be randomly assigned to one of two groups. The goal is to …

This study tests a new drug combination (venetoclax plus vincristine) in 40 adults with T-cell or B-cell acute lymphoblastic leukemia that has returned or not responded to prior therapy. The goal is to find the safest dose and see if the combination helps achieve remission. Parti…

This study tested whether a combination of temozolomide and capecitabine works better than the standard cisplatin and etoposide for people with advanced neuroendocrine cancer of the gut or pancreas that cannot be surgically removed. The trial enrolled 67 participants and was stop…

This study is for people with early-stage anal cancer. It compares a lower-dose chemotherapy and radiation treatment to the standard dose. The goal is to see if the lower dose works just as well to control the cancer but causes fewer side effects and improves quality of life. Abo…

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) works better than capecitabine in people with a certain type of triple-negative breast cancer that still remains after initial chemotherapy and surgery. About 415 participants with stage II or III bre…

This study tests whether doctors can safely stop standard anti-PD-1 immunotherapy earlier than usual for people with advanced melanoma that cannot be removed surgically. Using PET/CT scans and tumor biopsies as guides, researchers aim to see if shorter treatment still keeps the c…

This study tests three different drug combinations in people aged 70 or younger with newly diagnosed mantle cell lymphoma, a type of blood cancer. The goal is to see which combination works best to shrink tumors and keep the cancer from coming back. Participants receive chemother…

This study tests whether adding radiation therapy to standard chemotherapy helps people with HER2-negative esophageal or stomach cancer that has spread to a few other spots in the body (oligometastatic). About 314 participants will receive either chemotherapy alone or chemotherap…

This study looks at whether a concentrated form of green tea (green tea catechins) can stop or slow the growth of low-risk prostate cancer in men who are not receiving immediate treatment. About 360 men on active surveillance will take either the green tea extract or a placebo fo…

This phase 3 trial compared two different drug combinations (VRd and CRd) in 1087 people newly diagnosed with multiple myeloma. The goal was to see which combination works better at controlling the cancer and improving survival. After initial treatment, participants received main…

This study tests whether adding a chemotherapy drug (cabazitaxel) to a hormone therapy (abiraterone) works better than hormone therapy alone for men with advanced prostate cancer that has spread and stopped responding to initial treatment. About 223 men who have already received …

This study tested a simplified care strategy for patients with acute promyelocytic leukemia (APL), a rare blood cancer. The goal was to reduce deaths within the first month of treatment by using clear guidelines and support from APL experts. About 202 patients took part, and rese…

This study looks at whether taking crizotinib after surgery can help people with early-stage ALK-positive lung cancer live longer without the cancer returning. About 166 people who had their lung cancer removed will either take crizotinib or just be watched. The goal is to see if…

This study compares two chemotherapy regimens in 176 older patients whose pancreatic cancer has spread. One group gets gemcitabine plus nab-paclitaxel; the other gets a combination of 5-FU, leucovorin, and liposomal irinotecan. The goal is to see which treatment helps patients li…

This study looks at whether keeping blood pressure very low (below 120 mmHg) is better than the usual target (below 140 mmHg) for people with advanced kidney or thyroid cancer who are starting certain targeted cancer drugs. The goal is to reduce the risk of heart and kidney probl…

This study looked at whether giving high-dose interferon alfa-2b for four weeks helps prevent melanoma from coming back in people whose cancer was removed by surgery. About 1,150 patients with stage II or III melanoma took part. The goal was to see if the drug improves how long p…

This study tests whether a combination of two chemotherapy drugs (Gemcitabine and Docetaxel) works as well as the standard BCG treatment for high-grade non-muscle invasive bladder cancer. About 870 patients who have not received BCG before will be randomly assigned to one of the …

This study tests whether adding a stem cell transplant to standard rituximab maintenance therapy helps people with mantle cell lymphoma live longer. About 689 adults in first complete remission will be randomly assigned to receive either a transplant followed by rituximab or ritu…

This study looks at whether people with HER2-positive breast cancer (stage II to IIIa) who have no cancer left after initial chemotherapy and targeted therapy can safely receive fewer chemotherapy drugs after surgery. About 2,175 participants will get paclitaxel, trastuzumab, and…

This study tests whether adding darolutamide to standard hormone therapy (ADT) after prostate removal surgery can delay or prevent cancer from spreading in men at highest risk. About 27 participants will receive either darolutamide or a placebo alongside ADT. The goal is to see i…

This study compares two treatments for head and neck cancer that has spread to other parts of the body. All participants receive the immunotherapy drug pembrolizumab plus chemotherapy. Half also get targeted radiation to their tumors. The goal is to see if adding radiation helps …

This study tested two chemotherapy drugs—temozolomide alone or combined with capecitabine—in 144 people with advanced pancreatic neuroendocrine tumors that could not be removed by surgery. The goal was to see if the combination could delay tumor growth better than the single drug…

This study looks at people with HPV-positive throat cancer that has spread but can still be removed with surgery. After surgery, some patients get the usual high-dose radiation plus chemo, while others get a lower dose. The goal is to see if the lower dose works just as well to k…

This study compares two screening methods—abbreviated breast MRI and digital tomosynthesis (3D mammogram)—to see which better detects invasive breast cancer in women with dense breasts. About 1,500 women without symptoms are participating. The goal is to find a more effective and…

This study tests whether a special PET/CT scan (FDG-PET/CT) can predict how well HER2-positive breast cancer responds to chemotherapy before surgery. About 235 adults with stage II-III breast cancer will get the scan early in treatment. The goal is to see if the scan can help doc…

This study looks at whether a special type of MRI, called multiparametric MRI, can more accurately determine the stage of prostate cancer in people recently diagnosed. The goal is to help doctors better identify aggressive cancers and plan the right surgery. About 850 participant…

This study compares two types of mammograms—3D (tomosynthesis) and standard 2D—to see which is better at finding breast cancer early. Over 108,000 women without breast symptoms are taking part. The goal is to reduce advanced cancers and the need for extra tests or treatments.

This study tests whether a special type of PET/CT scan (FDG-PET/CT) can better measure how well treatment is working in breast cancer that has spread to the bones. About 138 people with this type of cancer will get the scan before and after starting treatment. The goal is to see …

This study looks at whether a special MRI scan can measure blood flow changes in brain tumors (glioblastoma) that have come back. The goal is to see if these changes can predict how well the drug bevacizumab is working, just two weeks after starting treatment. About 146 adults wi…

This study looks at how cancer treatment affects the finances of people with stage I to III colon or rectal cancer. Researchers will ask about 565 patients' costs and quality of life over a year. The goal is to understand the financial burden and help doctors better support patie…

This study looks at whether combining MRI scans with genetic tests can help doctors choose the best treatment for people with ductal carcinoma in situ (DCIS), a very early form of breast cancer that hasn't spread. About 368 participants will be followed to see if MRI findings cha…

This study looks at whether a genetic test can identify African American women with breast cancer who are more likely to develop nerve damage from taxane chemotherapy. Researchers compare two chemo drugs, docetaxel and paclitaxel, to see which causes fewer nerve problems. About 2…

This study was designed to look at how community cancer clinics test for biomarkers in common cancers like lung, breast, and colorectal cancer. The goal was to find out if testing is fast and accurate, and to spot any differences in how tests are done. However, the study was with…